Generation of a Dystrophin Mutant in Dog by Nuclear Transfer Using CRISPR/Cas9-Mediated Somatic Cells: A Preliminary Study

Int J Mol Sci. 2022 Mar 7;23(5):2898. doi: 10.3390/ijms23052898.

Abstract

Dystrophinopathy is caused by mutations in the dystrophin gene, which lead to progressive muscle degeneration, necrosis, and finally, death. Recently, golden retrievers have been suggested as a useful animal model for studying human dystrophinopathy, but the model has limitations due to difficulty in maintaining the genetic background using conventional breeding. In this study, we successfully generated a dystrophin mutant dog using the CRISPR/Cas9 system and somatic cell nuclear transfer. The dystrophin mutant dog displayed phenotypes such as elevated serum creatine kinase, dystrophin deficiency, skeletal muscle defects, an abnormal electrocardiogram, and avoidance of ambulation. These results indicate that donor cells with CRISPR/Cas9 for a specific gene combined with the somatic cell nuclear transfer technique can efficiently produce a dystrophin mutant dog, which will help in the successful development of gene therapy drugs for dogs and humans.

Keywords: CRISPR/Cas9; dog; dystrophin; mutant; somatic cell nuclear transfer.

MeSH terms

  • Animals
  • CRISPR-Cas Systems / genetics
  • Dogs
  • Dystrophin* / genetics
  • Dystrophin* / metabolism
  • Gene Editing
  • Muscle, Skeletal / metabolism
  • Muscular Dystrophy, Duchenne* / genetics
  • Muscular Dystrophy, Duchenne* / therapy
  • Nuclear Transfer Techniques

Substances

  • Dystrophin